<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240919041433&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240919041433&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 19 Sep 2024 08:14:34 +0000</lastbuilddate>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>If We Measure, We Can Improve</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1276-1278. doi: 10.1016/j.jacc.2024.07.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293888</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.031>10.1016/j.jacc.2024.07.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293888</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Celina M Yong</dc:creator>
<dc:creator>Sanket S Dhruva</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>If We Measure, We Can Improve</dc:title>
<dc:identifier>pmid:39293888</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.031</dc:identifier>
</item>
<item>
<title>Low-Density Lipoprotein Cholesterol Control as a Performance Measure: A National Analysis of the VHA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293887/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1272-1275. doi: 10.1016/j.jacc.2024.07.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293887/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293887</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.025>10.1016/j.jacc.2024.07.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293887</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sneha S Jain</dc:creator>
<dc:creator>Megan Skye</dc:creator>
<dc:creator>Natasha Din</dc:creator>
<dc:creator>Adam Furst</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Paul Heidenreich</dc:creator>
<dc:creator>Neil Kalwani</dc:creator>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Low-Density Lipoprotein Cholesterol Control as a Performance Measure: A National Analysis of the VHA</dc:title>
<dc:identifier>pmid:39293887</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.025</dc:identifier>
</item>
<item>
<title>Stopping Trials Early for Benefit: Insights From Recent Pivotal Trials in Chronic Kidney Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1268-1271. doi: 10.1016/j.jacc.2024.07.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293886</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.026>10.1016/j.jacc.2024.07.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293886</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Stopping Trials Early for Benefit: Insights From Recent Pivotal Trials in Chronic Kidney Disease</dc:title>
<dc:identifier>pmid:39293886</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.026</dc:identifier>
</item>
<item>
<title>Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>Many studies have shown an association of obstructive sleep apnea (OSA) with incident cardiovascular diseases, particularly when comorbid with insomnia, excessive sleepiness, obesity hypoventilation syndrome, and chronic obstructive pulmonary disease. Randomized controlled trials (RCTs) have demonstrated that treatment of OSA with positive airway pressure devices (CPAP) improves systemic hypertension, particularly in those with resistant hypertension who are adherent to CPAP. However, large RCTs...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1224-1240. doi: 10.1016/j.jacc.2024.07.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many studies have shown an association of obstructive sleep apnea (OSA) with incident cardiovascular diseases, particularly when comorbid with insomnia, excessive sleepiness, obesity hypoventilation syndrome, and chronic obstructive pulmonary disease. Randomized controlled trials (RCTs) have demonstrated that treatment of OSA with positive airway pressure devices (CPAP) improves systemic hypertension, particularly in those with resistant hypertension who are adherent to CPAP. However, large RCTs have not shown long-term benefits of CPAP on hard cardiovascular outcomes, but post hoc analyses of these RCTs have demonstrated improved hard outcomes in those who use CPAP adequately. In theory, low CPAP adherence and patient selection may have contributed to neutral results in intention-to-treat analyses. Only by further research into clinical, translational, and basic underlying mechanisms is major progress likely to continue. This review highlights the various treatment approaches for sleep disorders, particularly OSA comorbid with various other disorders, the potential reasons for null results of RCTs treating OSA with CPAP, and suggested approaches for future trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293885</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.024>10.1016/j.jacc.2024.07.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293885</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shahrokh Javaheri</dc:creator>
<dc:creator>Sogol Javaheri</dc:creator>
<dc:creator>David Gozal</dc:creator>
<dc:creator>Francisco Campos-Rodriguez</dc:creator>
<dc:creator>Miguel Angel Martinez-Garcia</dc:creator>
<dc:creator>Babak Mokhlesi</dc:creator>
<dc:creator>Reena Mehra</dc:creator>
<dc:creator>Walter T McNicholas</dc:creator>
<dc:creator>Virend K Somers</dc:creator>
<dc:creator>Phyllis C Zee</dc:creator>
<dc:creator>Peter Cistulli</dc:creator>
<dc:creator>Atul Malhotra</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39293885</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.024</dc:identifier>
</item>
<item>
<title>Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293884/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>The American Heart Association considers sleep health an essential component of cardiovascular health, and sleep is generally a time of cardiovascular quiescence, such that any deviation from normal sleep may be associated with adverse cardiovascular consequences. Many studies have shown that both impaired quantity and quality of sleep, particularly with obstructive sleep apnea (OSA) and comorbid sleep disorders, are associated with incident cardiometabolic consequences. OSA is associated with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1208-1223. doi: 10.1016/j.jacc.2024.02.059.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The American Heart Association considers sleep health an essential component of cardiovascular health, and sleep is generally a time of cardiovascular quiescence, such that any deviation from normal sleep may be associated with adverse cardiovascular consequences. Many studies have shown that both impaired quantity and quality of sleep, particularly with obstructive sleep apnea (OSA) and comorbid sleep disorders, are associated with incident cardiometabolic consequences. OSA is associated with repetitive episodes of altered blood gases, arousals, large negative swings in intrathoracic pressures, and increased sympathetic activity. Recent studies show that OSA is also associated with altered gut microbiota, which could contribute to increased risk of cardiovascular disease. OSA has been associated with hypertension, atrial fibrillation, heart failure, coronary artery disease, stroke, and excess cardiovascular mortality. Association of OSA with chronic obstructive lung disease (overlap syndrome) and morbid obesity (obesity hypoventilation syndrome) increases the odds of mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293884/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293884</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.059>10.1016/j.jacc.2024.02.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293884</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shahrokh Javaheri</dc:creator>
<dc:creator>Sogol Javaheri</dc:creator>
<dc:creator>Virend K Somers</dc:creator>
<dc:creator>David Gozal</dc:creator>
<dc:creator>Babak Mokhlesi</dc:creator>
<dc:creator>Reena Mehra</dc:creator>
<dc:creator>Walter T McNicholas</dc:creator>
<dc:creator>Phyllis C Zee</dc:creator>
<dc:creator>Francisco Campos-Rodriguez</dc:creator>
<dc:creator>Miguel Angel Martinez-Garcia</dc:creator>
<dc:creator>Peter Cistulli</dc:creator>
<dc:creator>Atul Malhotra</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39293884</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.059</dc:identifier>
</item>
<item>
<title>Takotsubo Cardiomyopathy: New Insights Into Long-Term Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1175-1177. doi: 10.1016/j.jacc.2024.05.074.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293883</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.074>10.1016/j.jacc.2024.05.074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293883</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter S Rahko</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Takotsubo Cardiomyopathy: New Insights Into Long-Term Outcomes</dc:title>
<dc:identifier>pmid:39293883</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.074</dc:identifier>
</item>
<item>
<title>Recovery of Left Ventricular Function and Long-Term Outcomes in Patients With Takotsubo Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Late recovery of LV function after TTS is associated with reduced short- and long-term survival. In TTS patients without early LV recovery, closer clinical follow-up might be considered.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1163-1174. doi: 10.1016/j.jacc.2024.05.075.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Takotsubo syndrome (TTS) is a form of transient left ventricular (LV) dysfunction that usually resolves within days to weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We aimed to assess the predictors and prognostic impact of time-to-LV recovery after TTS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Prospective serial imaging data from the nationwide, multicenter RETAKO (REgistry on TAKOtsubo Syndrome) were comprehensively reviewed to assess the timing of LV recovery. Multivariable logistic regression was used to assess factors associated with late (≥10 days) vs early (&lt;10 days) recovery. The long-term risk of all-cause mortality was compared between the late and early recovery groups using fully adjusted Cox models, and using flexible parametric survival models with recovery time included as a continuous variable.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1,463 patients included (median age 73 years, 13% men), 373 (25%) had late and 1,090 (75%) had early LV recovery. Older age, history of neurological disorders, bystander coronary artery disease, active cancer, physical triggers, elevated inflammatory biomarkers, cardiogenic shock, and lower LV ejection fraction at admission were independent predictors of late recovery. At 4-year follow-up, the adjusted risk of death was significantly higher in patients with late recovery compared with those with early recovery (16.0% vs 8.6%, adjusted HR: 1.31; 95% CI: 1.12-1.60), with the risk of death increasing by 8% for every additional 10-day delay in time-to-LV recovery (adjusted HR: 1.08; 95% CI: 1.04-1.13).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Late recovery of LV function after TTS is associated with reduced short- and long-term survival. In TTS patients without early LV recovery, closer clinical follow-up might be considered.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293882</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.075>10.1016/j.jacc.2024.05.075</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293882</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Manuel Almendro-Delia</dc:creator>
<dc:creator>Luis López-Flores</dc:creator>
<dc:creator>Aitor Uribarri</dc:creator>
<dc:creator>Oscar Vedia</dc:creator>
<dc:creator>Emilia Blanco-Ponce</dc:creator>
<dc:creator>María Del Carmen López-Flores</dc:creator>
<dc:creator>Antonio P Rivas-García</dc:creator>
<dc:creator>Clara Fernández-Cordón</dc:creator>
<dc:creator>Alessandro Sionis</dc:creator>
<dc:creator>Agustín C Martín-García</dc:creator>
<dc:creator>Ravi Vazirani</dc:creator>
<dc:creator>Miguel Corbí-Pascual</dc:creator>
<dc:creator>Jorge Salamanca</dc:creator>
<dc:creator>Alberto Pérez-Castellanos</dc:creator>
<dc:creator>Manuel Martínez</dc:creator>
<dc:creator>Víctor Manuel Becerra</dc:creator>
<dc:creator>David Aritza-Conty</dc:creator>
<dc:creator>Javier López-País</dc:creator>
<dc:creator>Marta Guillén-Marzo</dc:creator>
<dc:creator>Carmen Lluch-Requerey</dc:creator>
<dc:creator>Juan C García-Rubira</dc:creator>
<dc:creator>Iván J Núñez-Gil</dc:creator>
<dc:creator>RETAKO Investigators</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recovery of Left Ventricular Function and Long-Term Outcomes in Patients With Takotsubo Syndrome</dc:title>
<dc:identifier>pmid:39293882</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.075</dc:identifier>
</item>
<item>
<title>In vivo DNA replication dynamics unveil aging-dependent replication stress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293447/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>The genome duplication program is affected by multiple factors in vivo, including developmental cues, genotoxic stress, and aging. Here, we monitored DNA replication initiation dynamics in regenerating livers of young and old mice after partial hepatectomy to investigate the impact of aging. In young mice, the origin firing sites were well defined; the majority were located 10-50 kb upstream or downstream of expressed genes, and their position on the genome was conserved in human cells. Old mice...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 10:S0092-8674(24)00963-2. doi: 10.1016/j.cell.2024.08.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The genome duplication program is affected by multiple factors in vivo, including developmental cues, genotoxic stress, and aging. Here, we monitored DNA replication initiation dynamics in regenerating livers of young and old mice after partial hepatectomy to investigate the impact of aging. In young mice, the origin firing sites were well defined; the majority were located 10-50 kb upstream or downstream of expressed genes, and their position on the genome was conserved in human cells. Old mice displayed the same replication initiation sites, but origin firing was inefficient and accompanied by a replication stress response. Inhibitors of the ATR checkpoint kinase fully restored origin firing efficiency in the old mice but at the expense of an inflammatory response and without significantly enhancing the fraction of hepatocytes entering the cell cycle. These findings unveil aging-dependent replication stress and a crucial role of ATR in mitigating the stress-associated inflammation, a hallmark of aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293447/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293447</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.034>10.1016/j.cell.2024.08.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293447</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Giacomo G Rossetti</dc:creator>
<dc:creator>Noëlle Dommann</dc:creator>
<dc:creator>Angeliki Karamichali</dc:creator>
<dc:creator>Vasilis S Dionellis</dc:creator>
<dc:creator>Ainhoa Asensio Aldave</dc:creator>
<dc:creator>Tural Yarahmadov</dc:creator>
<dc:creator>Eddie Rodriguez-Carballo</dc:creator>
<dc:creator>Adrian Keogh</dc:creator>
<dc:creator>Daniel Candinas</dc:creator>
<dc:creator>Deborah Stroka</dc:creator>
<dc:creator>Thanos D Halazonetis</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>In vivo DNA replication dynamics unveil aging-dependent replication stress</dc:title>
<dc:identifier>pmid:39293447</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.034</dc:identifier>
</item>
<item>
<title>Fine-grained descending control of steering in walking Drosophila</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>Locomotion involves rhythmic limb movement patterns that originate in circuits outside the brain. Purposeful locomotion requires descending commands from the brain, but we do not understand how these commands are structured. Here, we investigate this issue, focusing on the control of steering in walking Drosophila. First, we describe different limb "gestures" associated with different steering maneuvers. Next, we identify a set of descending neurons whose activity predicts steering. Focusing on...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 13:S0092-8674(24)00962-0. doi: 10.1016/j.cell.2024.08.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Locomotion involves rhythmic limb movement patterns that originate in circuits outside the brain. Purposeful locomotion requires descending commands from the brain, but we do not understand how these commands are structured. Here, we investigate this issue, focusing on the control of steering in walking Drosophila. First, we describe different limb "gestures" associated with different steering maneuvers. Next, we identify a set of descending neurons whose activity predicts steering. Focusing on two descending cell types downstream of distinct brain networks, we show that they evoke specific limb gestures: one lengthens strides on the outside of a turn, while the other attenuates strides on the inside of a turn. Our results suggest that a single descending neuron can have opposite effects during different locomotor rhythm phases, and we identify networks positioned to implement this phase-specific gating. Together, our results show how purposeful locomotion emerges from specific, coordinated modulations of low-level patterns.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293446</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.033>10.1016/j.cell.2024.08.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293446</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Helen H Yang</dc:creator>
<dc:creator>Bella E Brezovec</dc:creator>
<dc:creator>Laia Serratosa Capdevila</dc:creator>
<dc:creator>Quinn X Vanderbeck</dc:creator>
<dc:creator>Atsuko Adachi</dc:creator>
<dc:creator>Richard S Mann</dc:creator>
<dc:creator>Rachel I Wilson</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Fine-grained descending control of steering in walking Drosophila</dc:title>
<dc:identifier>pmid:39293446</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.033</dc:identifier>
</item>
<item>
<title>Intracellular Ebola virus nucleocapsid assembly revealed by in situ cryo-electron tomography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293445/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>Filoviruses, including the Ebola and Marburg viruses, cause hemorrhagic fevers with up to 90% lethality. The viral nucleocapsid is assembled by polymerization of the nucleoprotein (NP) along the viral genome, together with the viral proteins VP24 and VP35. We employed cryo-electron tomography of cells transfected with viral proteins and infected with model Ebola virus to illuminate assembly intermediates, as well as a 9 Å map of the complete intracellular assembly. This structure reveals a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 12:S0092-8674(24)00973-5. doi: 10.1016/j.cell.2024.08.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Filoviruses, including the Ebola and Marburg viruses, cause hemorrhagic fevers with up to 90% lethality. The viral nucleocapsid is assembled by polymerization of the nucleoprotein (NP) along the viral genome, together with the viral proteins VP24 and VP35. We employed cryo-electron tomography of cells transfected with viral proteins and infected with model Ebola virus to illuminate assembly intermediates, as well as a 9 Å map of the complete intracellular assembly. This structure reveals a previously unresolved third and outer layer of NP complexed with VP35. The intrinsically disordered region, together with the C-terminal domain of this outer layer of NP, provides the constant width between intracellular nucleocapsid bundles and likely functions as a flexible tether to the viral matrix protein in the virion. A comparison of intracellular nucleocapsids with prior in-virion nucleocapsid structures reveals that the nucleocapsid further condenses vertically in the virion. The interfaces responsible for nucleocapsid assembly are highly conserved and offer targets for broadly effective antivirals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293445/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39293445</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.044>10.1016/j.cell.2024.08.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293445</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Reika Watanabe</dc:creator>
<dc:creator>Dawid Zyla</dc:creator>
<dc:creator>Diptiben Parekh</dc:creator>
<dc:creator>Connor Hong</dc:creator>
<dc:creator>Ying Jones</dc:creator>
<dc:creator>Sharon L Schendel</dc:creator>
<dc:creator>William Wan</dc:creator>
<dc:creator>Guillaume Castillon</dc:creator>
<dc:creator>Erica Ollmann Saphire</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Intracellular Ebola virus nucleocapsid assembly revealed by in situ cryo-electron tomography</dc:title>
<dc:identifier>pmid:39293445</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.044</dc:identifier>
</item>
<item>
<title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292498/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2963. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292498/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39292498</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2963>10.1001/jamacardio.2024.2963</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292498</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mahbod Rahimi</dc:creator>
<dc:creator>Vijay S Chauhan</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block</dc:title>
<dc:identifier>pmid:39292498</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2963</dc:identifier>
</item>
<item>
<title>Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Findings of this mendelian randomization study indicate that genetic predictors of cardiovascular disease were associated with increased psoriasis risk with no reciprocal effect or association with other IMIDs. Elucidating mechanisms underpinning this association could lead to novel therapeutic approaches in both diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2859. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The epidemiological link between immune-mediated diseases (IMIDs) and cardiovascular disease has often been attributed to systemic inflammation. However, the direction of causality and the biological mechanisms linking cardiovascular disease with IMIDs are incompletely understood. Given the robust epidemiological association and the growing body of supportive mechanistic evidence, psoriasis is an exemplary IMID model for exploring this relationship.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the bidirectional relationships between genetic predictors of psoriasis and the 2 major forms of cardiovascular disease, coronary artery disease (CAD) and stroke, and to evaluate the association between genetic predictors of cardiovascular disease with 9 other IMIDs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a genetic association study using mendelian randomization (MR), a powerful genetic tool to help distinguish causation from associations observed in epidemiological studies, to provide supportive evidence for causality between traits. The study conducted 2-sample MR analyses using summary-level data from large-scale genome-wide association meta-analysis studies (GWAS) for each trait. The analysis focused on individuals of European descent from GWAS meta-analyses, involving CAD, stroke, psoriasis, and 9 other IMIDs. Data were analyzed from January 2023 to May 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Genetic predictors of CAD, stroke, psoriasis, and 9 other IMIDs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes were the associations of genetic predictors of CAD and stroke with the risk of psoriasis and 9 other IMIDs, determined using inverse-variance weighted (IVW) MR estimates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 181 249 cases and 1 165 690 controls with CAD, 110 182 cases and 1 503 898 controls with stroke, 36 466 cases and 458 078 controls with psoriasis, for a total of approximately 3 400 000 individuals, and 9 other IMIDs. In contrast to previous assumptions, genetic predictors of psoriasis were found to have no association with CAD or stroke. In the reverse direction, genetic predictors of both CAD (MR estimate IVW odds ratio [OR], 1.07; 95% CI, 1.04-1.10; P = .003) and stroke (IVW OR, 1.22; 95% CI, 1.05-1.41; P = .01) were found to have risk-increasing associations with psoriasis. Adjusting for stroke rendered the associations of genetically predicted CAD with psoriasis risk nonsignificant (and vice versa), suggesting that a shared effect underlying genetic risk for CAD and stroke associates with increased psoriasis risk. No risk-increasing associations were observed for genetic predictors of cardiovascular disease with other common IMIDs, including rheumatoid arthritis and inflammatory bowel disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Findings of this mendelian randomization study indicate that genetic predictors of cardiovascular disease were associated with increased psoriasis risk with no reciprocal effect or association with other IMIDs. Elucidating mechanisms underpinning this association could lead to novel therapeutic approaches in both diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39292496</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2859>10.1001/jamacardio.2024.2859</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292496</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ravi Ramessur</dc:creator>
<dc:creator>Jake Saklatvala</dc:creator>
<dc:creator>Ashley Budu-Aggrey</dc:creator>
<dc:creator>Marek Ostaszewski</dc:creator>
<dc:creator>Lena Möbus</dc:creator>
<dc:creator>Dario Greco</dc:creator>
<dc:creator>Matladi Ndlovu</dc:creator>
<dc:creator>Satveer K Mahil</dc:creator>
<dc:creator>Jonathan N Barker</dc:creator>
<dc:creator>Sara Brown</dc:creator>
<dc:creator>Lavinia Paternoster</dc:creator>
<dc:creator>Nick Dand</dc:creator>
<dc:creator>Michael A Simpson</dc:creator>
<dc:creator>Catherine H Smith</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis</dc:title>
<dc:identifier>pmid:39292496</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2859</dc:identifier>
</item>
<item>
<title>Psoriasis and Atherosclerotic CV Disease-Risk Factor or Risk Marker?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292493/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2868. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292493/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39292493</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2868>10.1001/jamacardio.2024.2868</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292493</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael S Garshick</dc:creator>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Joel M Gelfand</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Psoriasis and Atherosclerotic CV Disease-Risk Factor or Risk Marker?</dc:title>
<dc:identifier>pmid:39292493</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2868</dc:identifier>
</item>
<item>
<title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292492/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2966. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292492/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39292492</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2966>10.1001/jamacardio.2024.2966</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292492</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeremy S Treger</dc:creator>
<dc:creator>Gaurav A Upadhyay</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block-Reply</dc:title>
<dc:identifier>pmid:39292492</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2966</dc:identifier>
</item>
<item>
<title>Tailoring Risk Prediction Models to Local Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The interpretable ML approach presented in this article enhanced the accuracy of the AHA-PREVENT model when applied to a local population while still preserving the risk associations found by the original model. This method has the potential to recalibrate other established risk tools and is implementable in electronic health record systems for improved cardiovascular risk assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2912. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Risk estimation is an integral part of cardiovascular care. Local recalibration of guideline-recommended models could address the limitations of existing tools.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To provide a machine learning (ML) approach to augment the performance of the American Heart Association's Predicting Risk of Cardiovascular Disease Events (AHA-PREVENT) equations when applied to a local population while preserving clinical interpretability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study used a New England-based electronic health record cohort of patients without prior atherosclerotic cardiovascular disease (ASCVD) who had the data necessary to calculate the AHA-PREVENT 10-year risk of developing ASCVD in the event period (2007-2016). Patients with prior ASCVD events, death prior to 2007, or age 79 years or older in 2007 were subsequently excluded. The final study population of 95 326 patients was split into 3 nonoverlapping subsets for training, testing, and validation. The AHA-PREVENT model was adapted to this local population using the open-source ML model (MLM) Extreme Gradient Boosting model (XGBoost) with minimal predictor variables, including age, sex, and AHA-PREVENT. The MLM was monotonically constrained to preserve known associations between risk factors and ASCVD risk. Along with sex, race and ethnicity data from the electronic health record were collected to validate the performance of ASCVD risk prediction in subgroups. Data were analyzed from August 2021 to February 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Consistent with the AHA-PREVENT model, ASCVD events were defined as the first occurrence of either nonfatal myocardial infarction, coronary artery disease, ischemic stroke, or cardiovascular death. Cardiovascular death was coded via government registries. Discrimination, calibration, and risk reclassification were assessed using the Harrell C index, a modified Hosmer-Lemeshow goodness-of-fit test and calibration curves, and reclassification tables, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the test set of 38 137 patients (mean [SD] age, 64.8 [6.9] years, 22 708 [59.5]% women and 15 429 [40.5%] men; 935 [2.5%] Asian, 2153 [5.6%] Black, 1414 [3.7%] Hispanic, 31 400 [82.3%] White, and 2235 [5.9%] other, including American Indian, multiple races, unspecified, and unrecorded, consolidated owing to small numbers), MLM-PREVENT had improved calibration (modified Hosmer-Lemeshow P >; .05) compared to the AHA-PREVENT model across risk categories in the overall cohort (χ23 = 2.2; P = .53 vs χ23 >; 16.3; P &lt; .001) and sex subgroups (men: χ23 = 2.1; P = .55 vs χ23 >; 16.3; P &lt; .001; women: χ23 = 6.5; P = .09 vs. χ23 >; 16.3; P &lt; .001), while also surpassing a traditional recalibration approach. MLM-PREVENT maintained or improved AHA-PREVENT's calibration in Asian, Black, and White individuals. Both MLM-PREVENT and AHA-PREVENT performed equally well in discriminating risk (approximate ΔC index, ±0.01). Using a clinically significant 7.5% risk threshold, MLM-PREVENT reclassified a total of 11.5% of patients. We visualize the recalibration through MLM-PREVENT ASCVD risk charts that highlight preserved risk associations of the original AHA-PREVENT model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The interpretable ML approach presented in this article enhanced the accuracy of the AHA-PREVENT model when applied to a local population while still preserving the risk associations found by the original model. This method has the potential to recalibrate other established risk tools and is implementable in electronic health record systems for improved cardiovascular risk assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39292486</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2912>10.1001/jamacardio.2024.2912</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292486</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Aniket N Zinzuwadia</dc:creator>
<dc:creator>Olga Mineeva</dc:creator>
<dc:creator>Chunying Li</dc:creator>
<dc:creator>Zareen Farukhi</dc:creator>
<dc:creator>Franco Giulianini</dc:creator>
<dc:creator>Brian Cade</dc:creator>
<dc:creator>Lin Chen</dc:creator>
<dc:creator>Elizabeth Karlson</dc:creator>
<dc:creator>Nina Paynter</dc:creator>
<dc:creator>Samia Mora</dc:creator>
<dc:creator>Olga Demler</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Tailoring Risk Prediction Models to Local Populations</dc:title>
<dc:identifier>pmid:39292486</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2912</dc:identifier>
</item>
<item>
<title>Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39291390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The data presented here demonstrate that preserving JP2-dependent E-C coupling by prohibiting the site-specific calpain cleavage of JP2 offers multifaceted beneficial effects, conferring cardiac protection against stress-induced proteolysis, hypertrophy, and HF. Our data also indicate that specifically targeting the primary calpain cleavage site of JP2 by gene therapy approaches holds great therapeutic potential as a novel precision medicine for treating HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 18. doi: 10.1161/CIRCULATIONAHA.124.069329. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Excitation-contraction (E-C) coupling processes become disrupted in heart failure (HF), resulting in abnormal Ca<sup>2+</sup> homeostasis, maladaptive structural and transcriptional remodeling, and cardiac dysfunction. Junctophilin-2 (JP2) is an essential component of the E-C coupling apparatus but becomes site-specifically cleaved by calpain, leading to disruption of E-C coupling, plasmalemmal transverse tubule degeneration, abnormal Ca<sup>2+</sup> homeostasis, and HF. However, it is not clear whether preventing site-specific calpain cleavage of JP2 is sufficient to protect the heart against stress-induced pathological cardiac remodeling in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Calpain-resistant JP2 knock-in mice (JP2<sup>CR</sup>) were generated by deleting the primary JP2 calpain cleavage site. Stress-dependent JP2 cleavage was assessed through in vitro cleavage assays and in isolated cardiomyocytes treated with 1 μmol/L isoproterenol by immunofluorescence. Cardiac outcomes were assessed in wild-type and JP2<sup>CR</sup> mice 5 weeks after transverse aortic constriction compared with sham surgery using echocardiography, histology, and RNA-sequencing methods. E-C coupling efficiency was measured by in situ confocal microscopy. E-C coupling proteins were evaluated by calpain assays and Western blotting. The effectiveness of adeno-associated virus gene therapy with JP2<sup>CR</sup>, JP2, or green fluorescent protein to slow HF progression was evaluated in mice with established cardiac dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: JP2 proteolysis by calpain and in response to transverse aortic constriction and isoproterenol was blocked in JP2<sup>CR</sup> cardiomyocytes. JP2<sup>CR</sup> hearts are more resistant to pressure-overload stress, having significantly improved Ca<sup>2+</sup> homeostasis and transverse tubule organization with significantly attenuated cardiac dysfunction, hypertrophy, lung edema, fibrosis, and gene expression changes relative to wild-type mice. JP2<sup>CR</sup> preserves the integrity of calpain-sensitive E-C coupling-related proteins, including ryanodine receptor 2, Ca<sub>V</sub>1.2, and sarcoplasmic reticulum calcium ATPase 2a, by attenuating transverse aortic constriction-induced increases in calpain activity. Furthermore, JP2<sup>CR</sup> gene therapy after the onset of cardiac dysfunction was found to be effective at slowing the progression of HF and superior to wild-type JP2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The data presented here demonstrate that preserving JP2-dependent E-C coupling by prohibiting the site-specific calpain cleavage of JP2 offers multifaceted beneficial effects, conferring cardiac protection against stress-induced proteolysis, hypertrophy, and HF. Our data also indicate that specifically targeting the primary calpain cleavage site of JP2 by gene therapy approaches holds great therapeutic potential as a novel precision medicine for treating HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39291390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39291390</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069329>10.1161/CIRCULATIONAHA.124.069329</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39291390</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jinxi Wang</dc:creator>
<dc:creator>Biyi Chen</dc:creator>
<dc:creator>Qian Shi</dc:creator>
<dc:creator>Grace Ciampa</dc:creator>
<dc:creator>Weiyang Zhao</dc:creator>
<dc:creator>Guangqin Zhang</dc:creator>
<dc:creator>Robert M Weiss</dc:creator>
<dc:creator>Tianqing Peng</dc:creator>
<dc:creator>Duane D Hall</dc:creator>
<dc:creator>Long-Sheng Song</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development</dc:title>
<dc:identifier>pmid:39291390</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069329</dc:identifier>
</item>
<item>
<title>Successful management of cardiac hydatidosis complicated by rupture and embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39291367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 18:ehae605. doi: 10.1093/eurheartj/ehae605. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39291367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39291367</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae605>10.1093/eurheartj/ehae605</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39291367</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Barnés-Navarro</dc:creator>
<dc:creator>Gerard Martí-Aguasca</dc:creator>
<dc:creator>Aitor Uribarri</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Successful management of cardiac hydatidosis complicated by rupture and embolism</dc:title>
<dc:identifier>pmid:39291367</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae605</dc:identifier>
</item>
<item>
<title>The gut microbiota in thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289543/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>The gut microbiota has emerged as an environmental risk factor that affects thrombotic phenotypes in several cardiovascular diseases. Evidence includes the identification of marker species by sequencing studies of the gut microbiomes of patients with thrombotic disease, the influence of antithrombotic therapies on gut microbial diversity, and preclinical studies in mouse models of thrombosis that have demonstrated the functional effects of the gut microbiota on vascular inflammatory phenotypes...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01070-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The gut microbiota has emerged as an environmental risk factor that affects thrombotic phenotypes in several cardiovascular diseases. Evidence includes the identification of marker species by sequencing studies of the gut microbiomes of patients with thrombotic disease, the influence of antithrombotic therapies on gut microbial diversity, and preclinical studies in mouse models of thrombosis that have demonstrated the functional effects of the gut microbiota on vascular inflammatory phenotypes and thrombus formation. In addition to impaired gut barrier function promoting low-grade inflammation, gut microbiota-derived metabolites have been shown to act on vascular cell types and promote thrombus formation. Therefore, these meta-organismal pathways that link the metabolic capacities of gut microorganisms with host immune functions have emerged as potential diagnostic markers and novel drug targets. In this Review, we discuss the link between the gut microbiota, its metabolites and thromboembolic diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289543/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39289543</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01070-6>10.1038/s41569-024-01070-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289543</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>My Phung Khuu</dc:creator>
<dc:creator>Nadja Paeslack</dc:creator>
<dc:creator>Olga Dremova</dc:creator>
<dc:creator>Corinne Benakis</dc:creator>
<dc:creator>Klytaimnistra Kiouptsi</dc:creator>
<dc:creator>Christoph Reinhardt</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The gut microbiota in thrombosis</dc:title>
<dc:identifier>pmid:39289543</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01070-6</dc:identifier>
</item>
<item>
<title>Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289542/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01082-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289542/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39289542</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01082-2>10.1038/s41569-024-01082-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289542</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women</dc:title>
<dc:identifier>pmid:39289542</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01082-2</dc:identifier>
</item>
<item>
<title>Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289541/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01081-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289541/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39289541</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01081-3>10.1038/s41569-024-01081-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289541</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Harman</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD</dc:title>
<dc:identifier>pmid:39289541</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01081-3</dc:identifier>
</item>
<item>
<title>Reproductive options and genetic testing for patients with an inherited cardiac disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289540/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919041433&amp;v=2.18.0.post9+e462414
      <description>In the past decade, genetic testing for cardiac disease has become part of routine clinical care. A genetic diagnosis provides the possibility to clarify risk for relatives. For family planning, a genetic diagnosis provides reproductive options, including prenatal diagnosis and preimplantation genetic testing, that can prevent an affected parent from having a child with the genetic predisposition. Owing to the complex genetic architecture of cardiac diseases, characterized by incomplete disease...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01073-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In the past decade, genetic testing for cardiac disease has become part of routine clinical care. A genetic diagnosis provides the possibility to clarify risk for relatives. For family planning, a genetic diagnosis provides reproductive options, including prenatal diagnosis and preimplantation genetic testing, that can prevent an affected parent from having a child with the genetic predisposition. Owing to the complex genetic architecture of cardiac diseases, characterized by incomplete disease penetrance and the interplay between monogenic and polygenic variants, the risk reduction that can be achieved using reproductive genetic testing varies among individuals. Globally, disparities, including regulatory and financial barriers, in access to reproductive genetic tests exist. Although reproductive options are gaining a prominent position in the management of patients with inherited cardiac diseases, specific policies and guidance are lacking. Guidelines recommend that prenatal diagnosis and preimplantation genetic testing are options that should be discussed with families. Health-care professionals should, therefore, be aware of the possibilities and feel confident to discuss the benefits and challenges. In this Review, we provide an overview of the reproductive options in the context of inherited cardiac diseases, covering the genetic, technical, psychosocial and equity considerations, to prepare health-care professionals for discussions with their patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289540/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919041433&v=2.18.0.post9+e462414">39289540</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01073-3>10.1038/s41569-024-01073-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289540</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Job A J Verdonschot</dc:creator>
<dc:creator>Aimee D C Paulussen</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Christine E M de Die-Smulders</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Reproductive options and genetic testing for patients with an inherited cardiac disease</dc:title>
<dc:identifier>pmid:39289540</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01073-3</dc:identifier>
</item>





























</channel>
</rss>